Literature DB >> 19295053

Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells.

Kim L Stocking1, Jon C Jones, Nancy E Everds, Bernard S Buetow, Martine P Roudier, Robert E Miller.   

Abstract

Intracardiac injection of human tumor cells into anesthetized nude mice is an established model of bone metastasis. However, intracardiac injection of some human tumor cell lines cause acute neurologic signs and high mortality, making some potentially relevant tumor cell lines unusable for investigation. We showed that intracardiac injection of tumor cells can induce a hypercoagulable state leading to platelet consumption and thromboemboli formation and that pretreatment with intravenous injection of low-molecular-weight heparin (LMWH; enoxaparin) blocks this state. In addition, intravenous injection of enoxaparin before intracardiac injection with 2 different small-cell lung carcinoma lines, H1975 and H2126, dramatically decreased mouse mortality while still generating bone metastases. Therefore, reduction of mortality by pretreatment with LMWH increases the types of cells that can be studied in this metastasis model and decreases the number of animals used.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295053      PMCID: PMC2703139     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  26 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Platelets express functional Toll-like receptor-4.

Authors:  Graciela Andonegui; Steven M Kerfoot; Kelly McNagny; Kirsten V J Ebbert; Kamala D Patel; Paul Kubes
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

Review 3.  Cancer and the prothrombotic state.

Authors:  Gregory Y H Lip; Bernard S P Chin; Andrew D Blann
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

Review 4.  The complex effects of heparins on cancer progression and metastasis in experimental studies.

Authors:  S M Smorenburg; C J Van Noorden
Journal:  Pharmacol Rev       Date:  2001-03       Impact factor: 25.468

5.  Preferential growth of mammary tumors in intact mammary fatpads.

Authors:  F R Miller; D Medina; G H Heppner
Journal:  Cancer Res       Date:  1981-10       Impact factor: 12.701

Review 6.  Animal models of bone metastasis.

Authors:  Thomas J Rosol; Sarah H Tannehill-Gregg; Bruce E LeRoy; Stefanie Mandl; Christopher H Contag
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

7.  In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer.

Authors:  Darlene E Jenkins; Shang-Fan Yu; Yvette S Hornig; Tony Purchio; Pamela R Contag
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 8.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.

Authors:  M C Bibby
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

9.  Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation.

Authors:  Sjoukje H Slofstra; Maarten F Bijlsma; Angelique P Groot; Pieter H Reitsma; Theo Lindhout; Hugo ten Cate; C Arnold Spek
Journal:  Blood       Date:  2007-07-19       Impact factor: 22.113

10.  Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis.

Authors:  Inder Sehgal; Timothy P Foster; Joseph Francis
Journal:  Cancer Cell Int       Date:  2006-08-23       Impact factor: 5.722

View more
  3 in total

1.  Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers.

Authors:  C Gadiko; S K Tippabhotla; S Thota; M Nakkawar; R Cheerla; M R Betha; V Vobalaboina
Journal:  J Drug Assess       Date:  2013-03-04

2.  Improvement of the therapeutic capacity of insulin-producing cells trans-differentiated from human liver cells using engineered cell sheet.

Authors:  Yu Na Lee; Hye-Jin Yi; Eun Hye Seo; Jooyun Oh; Song Lee; Sarah Ferber; Teruo Okano; In Kyong Shim; Song Cheol Kim
Journal:  Stem Cell Res Ther       Date:  2021-01-06       Impact factor: 6.832

3.  Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.

Authors:  Yao-Wen Chang; Pei-Wen Hsieh; Yu-Tsui Chang; Meng-Hong Lu; Tur-Fu Huang; Kowit-Yu Chong; Hsiang-Ruei Liao; Ju-Chien Cheng; Ching-Ping Tseng
Journal:  Oncotarget       Date:  2015-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.